Page 113 - Read Online

Page 12 of 15 Spencer et al. J Cancer Metastasis Treat 2022;8:2 https://dx.doi.org/10.20517/2394-4722.2021.174

In summary, after assessing the available evidence, it is clear that further scientific investigation is required
to determine the full role that MT1-MMP plays in OS progression and metastasis. Its expression and
proteolytic capacity are evident. However, MT1-MMP has significant therapeutic potential, particularly
through the exploitation of its proteolytic activity, which allows for the selective release of toxic agents at the
tumour site, helping to reduce off-target toxicity, which could drastically improve OS patient outcomes and
quality-of-life.

DECLARATIONS
Authors’ contributions
Wrote the manuscript: Spencer HLM
Concept: Falconer RA, Spencer HLM
Reviewed and edited manuscript: Spencer HLM, Shnyder SD, Loadman PM, Falconer RA
Final proofread: Spencer HLM, Falconer RA

Availability of data and materials
Not applicable.

Financial support and sponsorship
This work was supported by the Bone Cancer Research Trust (No. BCRT 6218).

Conflicts of interest
Falconer RA and Loadman PM declare that they are founding shareholders of Incanthera Plc. Other authors
declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2022.

REFERENCES
1. Misaghi A, Goldin A, Awad M, Kulidjian AA. Osteosarcoma: a comprehensive review. SICOT J 2018;4:12. DOI PubMed PMC
2. UK CR. Bone sarcoma statistics. Available from: https://www.cancerresearchuk.org/ [Last accessed on 6 Dec 2021].
3. Visse R, Nagase H, Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 2006;69:562-73. DOI
PubMed
4. Cerami E, Gao J, Dogrusoz U, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer
genomics data. Cancer Discov 2012;2:401-4. DOI PubMed PMC
5. Gao J, Aksoy BA, Dogrusoz U, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci
Signal 2013;6:pl1. DOI PubMed PMC
6. Kilpinen S, Autio R, Ojala K, et al. Systematic bioinformatic analysis of expression levels of 17,330 human genes across 9,783
samples from 175 types of healthy and pathological tissues. Genome Biol 2008;9:R139. DOI PubMed PMC
7. Gonzalez-Molina J, Gramolelli S, Liao Z, Carlson JW, Ojala PM, Lehti K. MMP14 in sarcoma: a regulator of tumor
microenvironment communication in connective tissues. Cells 2019;8:991. DOI PubMed PMC
8. Alaseem A, Alhazzani K, Dondapati P, Alobid S, Bishayee A, Rathinavelu A. Matrix metalloproteinases: a challenging paradigm of
cancer management. Semin Cancer Biol 2019;56:100-15. DOI PubMed
9. Gong Y, Chippada-Venkata UD, Oh WK. Roles of matrix metalloproteinases and their natural inhibitors in prostate cancer
progression. Cancers (Basel) 2014;6:1298-327. DOI PubMed PMC
10. Wang J, Shi Q, Yuan TX, et al. Matrix metalloproteinase 9 (MMP-9) in osteosarcoma: review and meta-analysis. Clin Chim Acta
2014;433:225-31. DOI PubMed
11. Zhang M, Zhang X. Association of MMP-2 expression and prognosis in osteosarcoma patients. Int J Clin Exp Pathol 2015;8:14965-